USPTO Examiner NATARAJAN MEERA - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19316633IL13 AND IL31 BISPECIFIC POLYPEPTIDES AND USES THEREOFSeptember 2025December 2025Allow300NoNo
19297899BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)August 2025February 2026Allow700YesNo
19293506MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2025January 2026Allow500YesNo
19281468METHODS FOR TREATING DIABETIC KIDNEY DISEASE AND GLOMERULAR DISEASEJuly 2025February 2026Allow710NoNo
19198507ANTIBODIES THAT BIND TNFRSF25May 2025July 2025Allow200YesNo
19193079BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)April 2025August 2025Allow301YesNo
19188549MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESApril 2025July 2025Allow310NoNo
19036915ANTIBODIES THAT BIND TNFRSF25January 2025April 2025Allow300YesNo
19032782MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
19032739MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
18987178ANTI-CD161 ANTIBODIES AND USES THEREOFDecember 2024February 2025Allow200NoNo
18905034TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USEOctober 2024April 2025Allow601YesNo
18821716OLIGOMERIC IgG FOR IMMUNOTHERAPEUTICS AND DIAGNOSTICSAugust 2024November 2025Allow1520NoNo
18805937MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18805883MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18793279ANTIBODIES TARGETING CCR2August 2024September 2024Allow200NoNo
18774143METHOD OF TREATING INFLAMMATORY BOWEL DISEASEJuly 2024September 2024Allow230YesNo
18656234ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 6May 2024August 2024Allow300NoNo
18618626Bispecific Constructs for Target and Complement EngagementMarch 2024January 2025Allow1021YesNo
18695296ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOFMarch 2024February 2026Allow2300YesNo
18609032MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYMarch 2024July 2024Allow410YesNo
18590865SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOFFebruary 2024August 2024Allow610YesNo
18582950ANTI-CD161 ANTIBODIES AND USES THEREOFFebruary 2024September 2024Allow701YesNo
18495086MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYOctober 2023February 2024Allow310NoNo
18457239FUSOBACTERIUM NUCLEATUM AMYLOID-LIKE FADA FOR DIAGNOSIS AND TREATMENT OF FN-MEDIATED PATHOGENESISAugust 2023February 2024Allow600YesNo
18456399THERAPEUTIC ANTIBODIES AND THEIR USESAugust 2023March 2026Allow3100NoNo
18449190METHODAugust 2023April 2024Allow810YesNo
18002472MULTI-SPECIFIC ANTIBODIES BINDING TO BCMAJune 2023February 2026Allow3800NoNo
18330367TIM-3-TARGETING ANTIBODIES AND USES THEREOFJune 2023June 2024Allow1221YesNo
18329781MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJune 2023September 2023Allow410YesNo
18121975METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNAMarch 2023August 2023Allow510NoNo
18184120BINDING AGENTS BINDING TO EPCAM AND CD137March 2023April 2025Allow2541YesYes
18018863PD-L1 BINDING AGENTS AND USES THEREOFJanuary 2023March 2026Allow3710NoNo
18101933ANTI-CSP ANTIBODIESJanuary 2023October 2025Allow3200YesNo
18006525IL2RG BINDING MOLECULES AND METHODS OF USEJanuary 2023October 2023Allow910YesNo
18006528IL2RB BINDING MOLECULES AND METHODS OF USEJanuary 2023October 2023Allow910NoNo
18157800ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOFJanuary 2023September 2023Allow710YesNo
18150616BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIESJanuary 2023March 2026Abandon3810NoNo
18092673METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNAJanuary 2023May 2023Allow400YesNo
18069570ANTI-cMET ANTIBODYDecember 2022March 2026Allow3910NoNo
18063797MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYDecember 2022April 2023Allow400YesNo
18063795MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYDecember 2022February 2023Allow200YesNo
18060204BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOFNovember 2022January 2026Allow3700YesNo
18000249ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASISNovember 2022March 2024Allow1510YesNo
18057566MONOCLONAL ANTIBODIES AGAINST BCMANovember 2022January 2026Allow3810NoNo
18055352ANTI-SIRP-ALPHA ANTIBODIESNovember 2022August 2025Allow3300YesNo
18052526ANTI-HUMAN CD19 ANTIBODIES WITH HIGH AFFINITYNovember 2022December 2025Allow3710YesNo
18051456ANTIGEN-BINDING MOLECULES THAT BIND TO PORPHYROMONAS GINGIVALISOctober 2022February 2026Allow3901YesNo
18048270HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCEROctober 2022December 2025Allow3820YesNo
17967418Multispecific Antigen-Binding Molecules for Cell Targeting and Uses ThereofOctober 2022December 2023Allow1421YesNo
18045093ANTI-TREM2 ANTIBODIES AND RELATED METHODSOctober 2022February 2025Allow2900NoNo
17934303ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAMESeptember 2022August 2023Allow1111YesNo
17933336SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEINSeptember 2022October 2025Allow3620NoNo
17930621METHODS FOR DETERMINING AND ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS IN TREATMENT OF CANCERSeptember 2022April 2023Allow710NoNo
17819545ANTIBODIES AGAINST N-ACETYLGLUCOSAMINE AND N-ACETYL-GALACTOSAMINEAugust 2022May 2025Allow3300YesNo
17816732NOVEL ANTI-CD3EPSILON ANTIBODIESAugust 2022August 2025Allow3600YesNo
17816731NOVEL ANTI-CD3EPSILON ANTIBODIESAugust 2022August 2025Allow3600YesNo
17812614MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOFJuly 2022January 2026Abandon4201NoNo
17811926FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOFJuly 2022October 2025Allow3900YesNo
17811606MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPYJuly 2022August 2024Allow2600NoNo
17811380MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJuly 2022October 2022Allow300NoNo
17859973CHIMERIC ANTIGEN RECEPTORS TARGETING GPRC5DJuly 2022December 2024Allow2910YesNo
17810377ANTI-CD38 BINDING DOMAINSJuly 2022January 2025Allow3110NoNo
17849467ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USESJune 2022September 2024Allow2700NoNo
17787226OPTIMIZED ANTI-CD3 ARM IN THE GENERATION OF T-CELL BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPYJune 2022December 2025Allow4210NoNo
17842351ANTI-CSP ANTIBODIESJune 2022October 2022Allow400YesNo
17831245ANTI-SIRP-ALPHA ANTIBODIESJune 2022October 2022Allow410NoNo
17825430RI-LABELED HUMANIZED ANTIBODYMay 2022July 2025Allow3720YesNo
17663396ANTI-FAP ANTIBODIES AND METHODS OF USEMay 2022January 2025Allow3210YesNo
17738588ANTI-CD47 ANTIBODIESMay 2022April 2025Abandon3510YesNo
17736882ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAMEMay 2022November 2025Allow4221YesNo
17716830Multispecific Antigen-Binding Molecules for Cell Targeting and Uses ThereofApril 2022April 2024Allow2441YesNo
17656682AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATIONMarch 2022January 2025Abandon3310NoNo
17695550ANTIBODIESMarch 2022December 2024Allow3310NoNo
17685029ANTI-GPRC5D MONOCLONAL ANTIBODIES AND USES THEREOFMarch 2022June 2022Allow300NoNo
17633797Therapeutic Antibodies Against OsteopontinFebruary 2022March 2025Allow3700YesNo
17580248T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULESJanuary 2022June 2024Allow2900NoNo
17570301METHODJanuary 2022December 2024Abandon3510NoNo
17562166BTLA ANTIBODIESDecember 2021December 2024Abandon3510NoNo
17644572BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOFDecember 2021September 2025Abandon4501NoNo
17550288ANTIBODIES AGAINST HUMAN CD38December 2021February 2025Allow3810NoNo
17547101ANTI-GLYCAN ANTIBODIES AND USES THEREOFDecember 2021November 2024Abandon3610NoNo
17615309PAN-NEURAMINIDASE INHIBITING ANTIBODIESNovember 2021August 2025Allow4510YesNo
17531380Anti-CD112R Compositions and MethodsNovember 2021July 2024Allow3210NoNo
17528976HUMANIZED ANTIBODIES AGAINST C-KITNovember 2021May 2024Allow3010NoNo
17610204AN ANTIGEN-BINDING MOLECULE, A PHARMACEUTICAL COMPOSITION, AND A METHODNovember 2021July 2025Allow4511NoNo
17502922INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021October 2023Abandon2421NoYes
17503025INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021July 2023Abandon2121NoNo
17502602INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021October 2023Abandon2421NoYes
17502860INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021July 2023Abandon2131YesNo
17496263Readily Isolated Bispecific Antibodies with Native Immunoglobulin FormatOctober 2021July 2024Allow3410NoNo
17494545ANTIBODIESOctober 2021December 2021Allow300NoNo
17490606ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOFSeptember 2021September 2024Abandon3510YesNo
17483101METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTSSeptember 2021November 2024Abandon3811YesNo
17469493RECOMBINANT POLYCLONAL PROTEINS TARGETING ZIKA AND METHODS OF USE THEREOFSeptember 2021April 2023Allow1921YesNo
17407651Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their UsesAugust 2021February 2026Allow5440NoNo
17402751COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPYAugust 2021March 2024Abandon3110NoNo
17310522COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING MANASSANTIN A AND IMMUNE CHECKPOINT INHIBITOR OR EPITHELIAL GROWTH FACTOR RECEPTOR INHIBITORAugust 2021February 2026Allow5421YesNo
17396127THERAPEUTIC COMPOUNDS AND METHODSAugust 2021December 2025Allow5221YesNo
17395400MULTISPECIFIC ANTIGEN-BINDING PROTEINSAugust 2021March 2024Allow3200YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NATARAJAN, MEERA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
6
(66.7%)
Examiner Reversed
3
(33.3%)
Reversal Percentile
49.3%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
65
Allowed After Appeal Filing
11
(16.9%)
Not Allowed After Appeal Filing
54
(83.1%)
Filing Benefit Percentile
20.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NATARAJAN, MEERA - Prosecution Strategy Guide

Executive Summary

Examiner NATARAJAN, MEERA works in Art Unit 1643 and has examined 950 patent applications in our dataset. With an allowance rate of 62.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner NATARAJAN, MEERA's allowance rate of 62.1% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NATARAJAN, MEERA receive 1.62 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NATARAJAN, MEERA is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +22.0% benefit to allowance rate for applications examined by NATARAJAN, MEERA. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.6% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 53.9% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 79.1% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 76.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.2% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.